Patents by Inventor José A. Halperin

José A. Halperin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020128256
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof which are specific, potent and safe inhibitors of the Ca2+-activated potassium channel (Gardos channel) of erythrocytes. The compounds can be used as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation.
    Type: Application
    Filed: June 13, 2001
    Publication date: September 12, 2002
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Publication number: 20020119953
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Application
    Filed: August 28, 2001
    Publication date: August 29, 2002
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellott, Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Patent number: 6331564
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P, the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Grant
    Filed: September 23, 1998
    Date of Patent: December 18, 2001
    Assignee: Ion Pharmaceuticals, Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellot, Jr., Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Patent number: 6256613
    Abstract: A medical consultation support system in which a client computer is employed transfer a structured request for consultation from a primary care physician to a supervisory host computer. The structured request may be accompanied by additional information related to the request, forming a transmittable, machine-readable collection of information relating to the consultation request. At the supervisory computer, the request is displayed for preliminary review by a receiving staff physician who designates specialist and retrieves selected supporting documentation which is related to the current consultation request from one or more databases of medical information accessible to the supervisory host computer. The supervisory computer then transmits the request for consultation, together with at least an identification of the selected supporting documentation, to the selected specialist for review, and thereafter receives the responsive comment from the selected specialist.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: July 3, 2001
    Assignee: Health Resources and Technology Inc.
    Inventors: Kenneth H. Falchuk, José A. Halperin
  • Patent number: 6127407
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: October 3, 2000
    Assignees: Ion Pharmaceuticals, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Patent number: 6066319
    Abstract: Methods for treatment of a subject with therapeutic or diagnostic agents by delivery of the therapeutic or diagnostic agents to the subject via sublytic amounts of terminal complement membrane attack acomplex (MAC) transmembrane channels are described. Also described are methods for delivery of therapeutic or diagnostic agents to cells in vitro via sublytic amounts of MAC transmembrane channels. Pharmaceutical preparations containing MAC transmembrane channel forming agents and kits for the formation of sublytic amounts of MAC transmembrane channels also are provided.
    Type: Grant
    Filed: April 30, 1996
    Date of Patent: May 23, 2000
    Assignee: President and Fellows of Harvard College
    Inventors: Jose A. Halperin, Daniel J. Goldstein, Juan A. Acosta
  • Patent number: 6043272
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: March 28, 2000
    Assignees: Ion Pharmaceuticals, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Patent number: 6028103
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: February 22, 2000
    Assignees: Children's Medical Center Corporation, Ion Pharmaceuticals, Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellot, Jr., Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Patent number: 5643936
    Abstract: The applicant has identified a particular class of imidazoles that inhibit angiogenesis. These imidazoles can be used to beneficially treat a variety of angiogenic conditions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 1, 1997
    Assignee: President and Fellows of Harvard College
    Inventors: Jose Halperin, Carlo Brugnara
  • Patent number: 5633274
    Abstract: The Applicant has identified a particular class of imidazoles that inhibit nonprostate cancer cell proliferation. These imidazoles can be used to beneficially treat a variety of cancers. The imidazoles can be administered in a variety of formulations, including long-term sustained release implants and anti-cancer cocktails.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: May 27, 1997
    Assignee: President and Fellows of Harvard College
    Inventors: Jose Halperin, Carlo Brugnara
  • Patent number: 5591763
    Abstract: The applicant has identified a particular class of imidazoles that inhibit anglogenesis. These imidazoles can be used to beneficially treat a variety of angiogenic conditions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 7, 1997
    Assignee: President and Fellows of Harvard College
    Inventors: Jose Halperin, Carlo Brugnara
  • Patent number: 5556871
    Abstract: A method of treating epithelial precancerous lesions is provided. The method involves the administration of certain imidazoles to an epithelial precancerous lesion. The preferred imidazoles are clotrimazole, miconazole, econazole and ketoconazole. The method of the invention is especially useful in treating actinic keratosis.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: September 17, 1996
    Assignee: President & Fellows of Harvard College
    Inventors: Jose Halperin, Carlo Brugnara, Harley Haynes
  • Patent number: 5512591
    Abstract: Identified are particular class of imidazoles that inhibit anglogenesis. These imidazoles can be used to beneficially treat a variety of angiogenic conditions.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: April 30, 1996
    Assignee: President and Fellows of Harvard College
    Inventors: Jose Halperin, Carlo Brugnara
  • Patent number: 5358959
    Abstract: The applicant has identified a particular class of imidazoles that inhibit endothelial cell, vascular smooth muscle cell and fibroblast proliferation. These imidazoles can be used to beneficially treat a variety of arteriosclerotic conditions.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: October 25, 1994
    Assignee: President and Fellows of Harvard University
    Inventors: Jose Halperin, Carlo Brugnara